Response of ponies to adjuvanted EHV-1 whole virus vaccine and challenge with virus of the homologous strain.

This study explores the immunological response of ponies vaccinated and revaccinated with a modified EHV-1, a type of virus that affects horses. The results showed mild clinical signs after exposure to the virus and the vaccination effectively prevented the virus from spreading through the blood. The vaccination also elicited high levels of virus-fighting antibodies and responses to all major components of the virus, as analyzed through a technique called western blotting.

Study Overview

• The research focused on the performance of a specific vaccine against Equid herpesvirus type 1 (EHV-1), a virus known to affect horses.
• Five yearling ponies were chosen as the main subjects for this study. The ponies were first vaccinated, then revaccinated six weeks later with a modified form of the EHV-1 strain.
• After an additional six weeks, these ponies, along with three control ponies of the same age, were exposed to the virus to observe the effects.
• The researchers monitored the ponies for clinical signs, biological changes, and changes in blood serum, an aspect that can hint at how the body is reacting immunologically.

Results of the Study

• Upon exposure to the virus, clinical signs were mild in both the vaccinated and the control group. This indicates that the severity of the disease was not drastically different between the two groups.
• One of the main findings was that the vaccinated ponies did not present cell-associated viraemias, which indicates that the virus did not replicate and circulate in the blood of the vaccinated group. This suggests that the vaccine was successful in preventing widespread infection within the animal.
• The vaccination was also shown to have induced high levels of two types of antibodies: complement-fixing (CF) and virus-neutralizing (VN). The presence of these antibodies indicates a robust immune response post-vaccination.
• Furthermore, the researchers identified a response to all major viral glycoproteins, as seen through western blot analysis. This assures that the vaccine elicited a broad immune response, equipping the body to counter the multiple components of the virus.